case_images: PMC11004978_01
case_images: A) Axial PET-CT scan images of chest from March 2022 showing new 9 mm RUL and stable right paramediastinal disease; B) Percutaneous needle prior to delivery of PEF from June 2022; Follow-up images performed at 3-months (C) and 6-months (D), and 12 months (E).
case_images: gr1.jpg
case_images: PMC11004978_01_gr1.jpg
case_images: fig1
case_images: PET-CT imaging performed after 6 months identified a new 9 mm, FDG-avid (SUV max 5.5) nodule in right upper lobe (RUL) of the lung (Fig. 1A) consistent with early progression. The percutaneous needle was positioned (Fig. 1B) and the first PEF dose was delivered to the distal portion of tumor and a second dose after retracting the needle 5 mm. CT-scans of the chest revealed modest regression of RUL lesion (8 x 4 mm) with stable para-mediastinal disease (2.3 x 2.5 cm) (Fig. 1C). Six-month follow-up images in January 2023 were unchanged (Fig. 1D) and durvalumab was discontinued. Surveillance imaging at 12 months post-PEF treatment showed stable RUL (8 x 4 mm) and right paramediastinal (2.6 x 2.4 x 5.6 cm) disease and no new findings (Fig. 1E).